STRO
Sutro BiopharmaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
The bull case is that STRO-004 shows tolerable early safety and enough activity to support best-in-class TF ADC positioning, while Astellas milestones and 2028 runway reduce immediate dilution pressure and allow multiple shots on goal through 2026 [#8-K-2026-03-23].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +18.8.
What can break
Future capital needs remain significant despite runway extension
Momentum
27
Value
41
Sentiment
65
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $27.00 · Bull $38.00 · Bear $18.00
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $47.75
Why
Momentum27 · Δ7d -44.7
Value41 · Δ7d +0.1
Sentiment65 · Δ7d +18.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
27
26% active weight
Current posture
7d trendSoftening
Δ7d
-44.7
Δ21d
-32.7
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
65
34% active weight
Current posture
7d trendImproving
Δ7d
+18.8
Δ21d
+33.8
Why this grade
Composite grade D. Momentum 27.2 / Value 41.1 / Sentiment 64.8
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$381.12M
Beta
1.55
Shares Out
16.57M
P/E (TTM) · Derived
-1.0
P/S (TTM)
0.88
P/FCF (TTM) · Derived
-1.42
Rev YoY
-16.5%
EPS YoY
-67.8%
Gross Margin
+93.3%
Op Margin
-175.7%
Net Debt
$93.78M
Current Ratio
3.12
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology